Trials / Unknown
UnknownNCT05131243
the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer
the Role of ctDNA in Predicting the Recurrence Risk of Stage Ⅱ and Ⅲ Colorectal Cancer and the Dynamic Changes in ctDNA of Patients With Adjuvant Chemotherapy
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Fujian Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to observe the relationship between ctDNA as a molecular marker of colorectal cancer and the risk of postoperative recurrence.
Detailed description
In this clinical study, ctDNA will be detected in postoperative patients with stage Ⅱ and Ⅲ colorectal cancer to evaluate the correlation between ctDNA and the risk of postoperative recurrence. According to the dynamic changes of ctDNA after adjuvant chemotherapy, the correlation between ctDNA and postoperative DFS will be compared, and the feasibility of ctDNA as a molecular marker to evaluate the risk of postoperative recurrence of colorectal cancer will be investigated.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Chemotherapy time | 6 months of chemotherapy |
| PROCEDURE | Chemotherapy time | 3 months of chemotherapy |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2023-05-01
- Completion
- 2023-05-01
- First posted
- 2021-11-23
- Last updated
- 2021-11-23
Source: ClinicalTrials.gov record NCT05131243. Inclusion in this directory is not an endorsement.